Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Greenphire and Ernst & Young Announce Strategic Partnership

Published: Wednesday, July 10, 2013
Last Updated: Wednesday, July 10, 2013
Bookmark and Share
Partnership will combine eClinicalGPS technology with the global intellectual property and expertise of Ernst & Young.

Greenphire has announced the launch of a strategic partnership with Ernst & Young. The partnership will combine Greenphire’s industry leading eClinicalGPS technology with the global intellectual property and expertise of Ernst & Young’s advisory practice for clients in the pharmaceutical industries.

Within the scope of the partnership, Greenphire’s clients will have access to specialists within Ernst & Young’s global consulting and advisory practice that focuses on global HCP transparency regulatory compliance (e.g. - The US Sunshine Act).

This relationship will increase the strength of Greenphire’s eClinicalGPS technology by giving clients the ability to leverage Ernst & Young’s market leading advisory practice in concert with Greenphire’s market leading payment and data aggregation technology.

Ernst & Young’s advisory practice will further assist Greenphire’s clients to comply with 75+ transparency regulations globally.

Additionally, Ernst & Young’s extensive proprietary research will be routed into a new Greenphire technology solution. The technology, currently in development, will be a first-of-its-kind, web-based SaaS solution to manage and track all transactional interactions between pharmaceutical companies and HCPs, including cash transactions and transfers of value, on a global basis across all aspects of pharmaceutical operations.

Sam Whitaker, co-founder and CEO of Greenphire, comments: "We are delighted to work with Ernst & Young in what is sure to be an industry-changing partnership. Global transparency regulations are constantly evolving, and our clients are very much in need of a reliable source of information on how to adjust their processes to remain compliant. We are very excited to be able to offer them access to an incredible resource such as Ernst & Young.”

Martin Holyoake, Partner at Ernst & Young said: “We are proud to be working with Greenphire to help ensure that clients successfully navigate the complicated legislative landscape and deliver value. The deep technical knowledge and grounded relationships formed as a result of our long standing presence in this sector will help clients translate regulation, meet their obligations and gain real insight. We look forward to working with Greenphire to bring tangible benefits to our clients.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Greenphire Awards $35,000 to Three Health and Wellness Nonprofits
NO MORE received a donation of $20,000 to further its mission to end domestic violence and sexual assault.
Wednesday, June 25, 2014
Greenphire Appoints Senior Director of Business Development in Europe
Alex Livingstone brings more than 12 years of eClinical software, pharmaceutical and biotechnology industry experience to the company.
Thursday, October 10, 2013
Greenphire Named One of the Fastest-Growing U.S Companies
The company has been ranked in the 2013 Inc. Magazine 500 list of the fastest-growing private companies in the U.S.
Wednesday, August 21, 2013
Greenphire and Oracle to Work Together
New partnership to automate clinical trial planning, budgeting and payments.
Tuesday, June 25, 2013
Greenphire and IMS Health Announce Strategic Integration
Launch of strategic integration of eClinicalGPS and GrantPlan.
Friday, June 21, 2013
Greenphire's John Samar Named CFO of the Year Finalist
The Philadelphia Business Journal awards honour professionals who have displayed outstanding performance in their roles as corporate financial leaders.
Wednesday, May 29, 2013
Greenphire CEO Selected as Finalist in Ernst & Young Awards
CEO Sam Whitaker has been selected as a finalist for the Ernst & Young Entrepreneur of the Year Awards 2013 in the Greater Philadelphia region.
Friday, May 17, 2013
Greenphire Announces New London Office
Plans to facilitate expansion in Europe.
Tuesday, May 07, 2013
Greenphire Appoints UK-based Global Product Manager
Appointment of Rory O’Hare to facilitate European growth.
Thursday, February 21, 2013
Greenphire Supports Proposed EU Legislation to Reduce Clinical Trial Administration
The proposed legislation expected to be enacted by 2016.
Friday, July 27, 2012
Greenphire Appoints Chief Commercial Officer
Appointment of John M Blakeley to the role of Chief Commercial Officer.
Thursday, July 12, 2012
Greenphire and Merge Healthcare Form Exclusive Partnership
Partnership to integrate clinical payment and EDC platforms.
Wednesday, May 09, 2012
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!